The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects
about
The role of lamotrigine in the management of bipolar disorderPrenatal exposure to lamotrigine: effects on postnatal development and behaviour in rat offspringClinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptivesCarbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleedingPossible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database.Pregnancy, epilepsy, and anticonvulsants.Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and EfavirenzPrioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugsHormones, seizures, and lamotrigine: Oh, my!Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.Pharmacokinetics and drug interactions with zonisamide.Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.Drug interactions involving the new second- and third-generation antiepileptic drugs.Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.Anti-epileptic drugs and hormonal treatments.Modern management of juvenile myoclonic epilepsy.Reasons for discontinuation of reversible contraceptive methods by women with epilepsy.Perspectives on variability in pharmacokinetics of an oral contraceptive product.Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: A matched case-control study.Women with epilepsy initiating a progestin IUD: A prospective pilot study of safety and acceptability.Contraceptive practices of women with epilepsy: Findings of the epilepsy birth control registry.The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.Caring for transgender patients with epilepsy.Bipolar disorder in women.Contraception for women with epilepsy: counseling, choices, and concerns.Hormone replacement therapy in women with epilepsy.Antiepileptika bei Frauen im gebärfähigen Alter und in der Schwangerschaft
P2860
Q24658110-0F290EA0-8649-49B9-A5A1-41E853ADAD82Q33711330-251F2254-2A57-4195-B271-9B3784A9949FQ33765400-07AF006D-86C7-4931-8CAE-FAF976D1620CQ34676717-62A7064C-8A32-4888-A214-8D2EA65923F8Q35120648-F9AE72F4-BFA8-447D-A4A0-25C0C6377D64Q35236942-5105780F-FF4D-46C6-AFA1-769C9512D88FQ35821164-A5DF252A-DB05-4369-831B-78EFC314827DQ36024450-C5964EBD-02C1-4526-A09A-2541E1B3B2FBQ36453496-A22DEE8D-557B-4E14-9F08-4DB9EE1BF699Q36662898-22BD215B-13E1-4BC0-83E2-B4A716813783Q36744156-C0654BDF-9340-4864-80AD-7FCC30E4BDF3Q37186130-2783C3B8-E628-4CAC-BDA9-23A489B77E02Q37313452-8129AC83-287B-4134-861C-B5AA13DCC69CQ37658910-DD02A10A-06F2-49D5-9F01-2A7816568D90Q38116456-5B186CFB-BF8D-4FDF-B8DE-3AA771A608D7Q38200537-C098FC84-7472-4C99-B62F-D2AE63926946Q38809047-28CFD200-908D-4E2B-8705-7B35F5E313CAQ38859883-701E793B-76BF-4091-BADF-2BC2FAFBBA4AQ38913410-D136032E-AF6B-4BC0-80DC-D475C8563066Q39224683-1532AC91-45B9-4119-8AAB-58ECA0D7FA98Q39345923-F167A095-F49C-4609-A775-D8AAAF3172DCQ39994611-F728BCFD-69BF-4F3D-A159-DC724E0B02D2Q43446224-0DC48D58-BF2F-41BA-9FD0-D48EF6B49ABBQ46558204-F9D9CDF4-C9F5-463B-8AF6-3FBA4BD36D79Q46587398-33991676-5370-4075-B460-7D9603D06598Q47677878-090E8821-CD35-44A6-8EFA-815B6F8ADEE5Q48191720-8F259F78-3F94-4219-AE10-AE8DB525638EQ49540132-0471EA44-B195-4610-96BE-78B0AA18A9D6Q53191997-42E5C0CA-5DAE-4C15-ACAE-C9EA9FA79999Q56423205-1622D57B-912A-4EB7-A19A-307C4ED87E2D
P2860
The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The pharmacokinetic and pharma ...... ive in healthy female subjects
@ast
The pharmacokinetic and pharma ...... ive in healthy female subjects
@en
The pharmacokinetic and pharma ...... ive in healthy female subjects
@nl
type
label
The pharmacokinetic and pharma ...... ive in healthy female subjects
@ast
The pharmacokinetic and pharma ...... ive in healthy female subjects
@en
The pharmacokinetic and pharma ...... ive in healthy female subjects
@nl
prefLabel
The pharmacokinetic and pharma ...... ive in healthy female subjects
@ast
The pharmacokinetic and pharma ...... ive in healthy female subjects
@en
The pharmacokinetic and pharma ...... ive in healthy female subjects
@nl
P2093
P2860
P1476
The pharmacokinetic and pharma ...... ive in healthy female subjects
@en
P2093
Jagdev Sidhu
Richard Philipson
Sunita Singh
P2860
P356
10.1111/J.1365-2125.2005.02539.X
P407
P577
2006-02-01T00:00:00Z